We are live on ! Find out more
VMI

VHCP Management II Portfolio holdings

AUM $379M
1-Year Est. Return 421.62%
This Fund
S&P 500
This Quarter Est. Return
+255.77%
1 Year Est. Return
+421.62%
3 Year Est. Return
+2,333.62%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$379M
AUM Growth
+$117M
Cap. Flow
-$59M
Cap. Flow %
-15.54%
Top 10 Hldgs %
94.12%
Holding
29
New
8
Increased
1
Reduced
7
Closed
9

Top Buys

1
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$22.3M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$3.59M
3
RLMD icon
Relmada Therapeutics
RLMD
+$3.49M
4
ADVM
Adverum Biotechnologies
ADVM
+$3.38M
5
MRSN
Mersana Therapeutics
MRSN
+$2.7M

Top Sells

1
ASND icon
Ascendis Pharma A/S
ASND
+$22.6M
2
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$16M
3
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$13.2M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$12.4M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$8.24M

Sector Composition

1 Healthcare 99.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TXG icon
1
10x Genomics
TXG
$5.65B
$136M 35.91%
1,786,431
– –
AXSM icon
2
Axsome Therapeutics
AXSM
$12.2B
$81.2M 21.42%
785,981
-106,965
-12% -$4.32M
CNST
3
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$70.7M 18.64%
1,500,631
+773,954
+107% +$22.3M
BHVN
4
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$25.2M 6.64%
462,903
-250,000
-35% -$12.4M
SWAV
5
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$12.7M 3.34%
288,838
-357,589
-55% -$13.2M
ISEE
6
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$8.62M 2.27%
+1,004,299
New +$3.59M
KALV
7
DELISTED
KalVista Pharmaceuticals
KALV
$6.52M 1.72%
366,268
-10,621
-3% -$139K
OBSV
8
DELISTED
ObsEva SA Ordinary Shares
OBSV
$6.01M 1.58%
1,573,639
-678,821
-30% -$3.53M
MRSN
9
DELISTED
Mersana Therapeutics
MRSN
$5.29M 1.39%
+36,901
New +$2.7M
SPRO icon
10
Spero Therapeutics
SPRO
$90.9M
$4.56M 1.2%
474,015
– –
RLMD icon
11
Relmada Therapeutics
RLMD
$573M
$4.48M 1.18%
+114,876
New +$3.49M
ADVM
12
DELISTED
Adverum Biotechnologies
ADVM
$4.42M 1.16%
+38,362
New +$3.38M
MRNS
13
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$3.21M 0.85%
371,669
– –
FTSV
14
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$3.06M 0.81%
+77,714
New +$1.25M
MIST icon
15
Milestone Pharmaceuticals
MIST
$154M
$2.38M 0.63%
148,560
– –
NXTC icon
16
NextCure
NXTC
$25.1M
$2.04M 0.54%
+3,021
New +$1.52M
MYOV
17
DELISTED
Myovant Sciences Ltd.
MYOV
$1.19M 0.31%
+76,768
New +$774K
ETNB
18
DELISTED
89bio
ETNB
$1.08M 0.29%
+41,235
New +$1.15M
BLPH
19
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$230K 0.06%
43,939
-232,686
-84% -$1.48M
PTGX icon
20
Protagonist Therapeutics
PTGX
$8.49B
$227K 0.06%
32,211
-394,570
-92% -$3.92M
ASND icon
21
Ascendis Pharma A/S
ASND
$17B
– –
-234,591
Closed -$22.6M
BCRX icon
22
BioCryst Pharmaceuticals
BCRX
$2.31B
– –
-2,874,602
Closed -$8.24M
KNSA icon
23
Kiniksa Pharmaceuticals
KNSA
$4.7B
– –
-540,461
Closed -$4.6M
KA
24
DELISTED
Kineta, Inc. Common Stock
KA
– –
-934
Closed -$110K
TCDA
25
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-118,886
Closed -$3.67M
1
2

Similar funds

ACPU
Arrowgrass Capital Partners (US) Dover, Delaware $380M AUM 20.87% 1-Year Est. Return
PI
PHH Investments Addison, Texas $378M AUM 19.74% 1-Year Est. Return
SC
Southside Capital Miami Beach, Florida $382M AUM 30.29% 1-Year Est. Return
FFSOTS
Fiduciary Financial Services of The Southwest Dallas, Texas $382M AUM 25.98% 1-Year Est. Return
PC
Passport Capital San Francisco, California $394M AUM 50.67% 1-Year Est. Return
WC
Whitnell & Co Oak Brook, Illinois $326M AUM 25.97% 1-Year Est. Return
VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
LB
Landmark Bank Columbia, Missouri $444M AUM 30.12% 1-Year Est. Return

VHCP Management II's Q4 2019 Portfolio in Review

As of Q4 2019, VHCP Management II held 29 positions worth $379M, up 45% from $262M the previous quarter. Its ten largest holdings account for 94% of the portfolio.

VHCP Management II withdrew a net $59M in Q4 2019, closing 9 positions and reducing 7 holdings. Its most notable exit was Ascendis Pharma A/S, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier.

Against the trend, VHCP Management II opened a new position in IVERIC bio, Inc. Common Stock worth $8.62M.

  • VHCP Management II's largest Q4 2019 buy was IVERIC bio, Inc. Common Stock: 1,004,299 shares worth $8.62M.
  • VHCP Management II added most to Constellation Pharmaceuticals, Inc. in Q4 2019, an estimated $22.3M increase.
  • VHCP Management II's biggest Q4 2019 reduction was Shockwave Medical, Inc. Common Stock, cutting an estimated $13.2M.
  • VHCP Management II fully exited Ascendis Pharma A/S in Q4 2019, selling an estimated $22.6M.
  • VHCP Management II's ten largest holdings make up 94% of its $379M portfolio in Q4 2019.
  • VHCP Management II opened 8 new positions and closed 9 in Q4 2019.
  • VHCP Management II's portfolio value rose 45% quarter-over-quarter to $379M.

Based on VHCP Management II's 13F filing for Q4 2019, filed 13 Feb 2020.